Katsuya Nagaoka

Assistant Professor

Kumamoto University Hospital

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Katsuya Nagaoka is an Assistant Professor at Kumamoto University Hospital in Japan. His research focuses on various aspects of hepatology, including the clinical significance of hepatitis B and C viruses, metabolic liver diseases, and the application of artificial intelligence in cancer detection. Recent publications highlight his work on novel biomarkers for liver diseases and the impact of gut microbiota on liver health.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (9)

Mark Olsen

Associate Professor

Midwestern University

UNITED STATES

View details

Hiroshi Mori

National Institute of Genetics

JAPAN

View details

richard terek

Brown University

UNITED STATES

View details

Shinya Oki

特定准教授 / Program-Specific Associate Professor

Kyoto University

JAPAN

View details

Mitsuyoshi Nakao

Kumamoto University

JAPAN

View details

Yasuhito Tanaka

JAPAN

View details

Kenyu Hashimoto

Kumamoto University Hospital

JAPAN

View details

Masao Matsuoka

Kumamoto University

JAPAN

View details

Takehisa Watanabe

Kumamoto University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Katsuya Nagaoka

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

ASPH Is a Metastatic Factor and Therapeutic Target in Chondrosarcoma

Evaluation of fully automated chemiluminescent enzyme immunoassays for hepatitis B core-related antigen components, phosphorylated and non-phosphorylated hepatitis B core antigens: clinical significance and dynamics during hepatitis B e antigen seroconversion

Restoration of the gut-microbiota-liver axis after hepatitis C virus eradication

Serum alpha‐fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitis

Liver TET1 promotes metabolic dysfunction-associated steatotic liver disease

Impact of HPV status on oropharyngeal cancer detection via gastrointestinal endoscopy: a retrospective study

Optimizing AI models to predict esophageal squamous cell carcinoma risk by incorporating small datasets of soft palate images

A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA

Amputation neuroma with a difficult differential diagnosis from perihilar cholangiocarcinoma: a case report,肝門部領域胆管癌との鑑別に苦慮した断端神経腫の 1 例

An RNA-degrading enzyme emerges as a biomarker in a study of human hepatitis virus B

Serum inducible protein 10 kDa/C‐X‐C motif chemokine 10 levels predict regression of M2BPGi‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents

Possible Association of Mutations in the MEFV Gene with the Intestinal Phenotype of Behçet’s Disease and Refractoriness to Treatment

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma

Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma

Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma

Mitochondrial stress induces AREG expression and epigenomic remodeling through c-JUN and YAP-mediated enhancer activation

Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity

Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity

Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins

Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins

Collaborators (9)

Mark Olsen

Hiroshi Mori

richard terek

Shinya Oki

Mitsuyoshi Nakao

Yasuhito Tanaka

Kenyu Hashimoto

Masao Matsuoka

Takehisa Watanabe

Make your next move.